ARTICLE |
a Departments of Pediatrics
b Neonatology
d Internal Medicine
e Pediatric Cardiology Unit
f Pediatric Intensive Care Unit, Hadassah and the Hebrew University Medical Center, Jerusalem, Israel
c Biochemistry Laboratory
h Pediatric Cardiology Unit, Shaare Zedek Medical Center, Jerusalem, Israel
g Pediatric Intensive Care Unit, Western Galilee Hospital, Naharia, Israel
| ABSTRACT |
|---|
|
|
|---|
PATIENTS AND METHODS. Pediatric patients admitted to an ICU with sepsis or acute left ventricular dysfunction were evaluated clinically, and the grade of systemic inflammatory-response syndrome was determined. Echocardiography was performed, and their levels of N-terminal pro-B-type natriuretic peptide were measured. The N-terminal pro-B-type natriuretic peptide level was also measured in patients with simple febrile illness.
RESULTS. There were 10 patients with sepsis and 10 with acute left ventricular dysfunction. The age of the patients was similar, and systemic inflammatory-response syndrome grading was not different (sepsis: 2.8 ± 0.4; acute left ventricular dysfunction: 2.6 ± 0.7). N-terminal pro-B-type natriuretic peptide levels were elevated in patients with sepsis (median: 6064 pg/mL; range: 49560417 pg/mL) but were significantly higher in patients with acute left ventricular dysfunction (median: 65630 pg/mL; range: 15125288000). The area under the receiver operating characteristics curve for the diagnosis of acute left ventricular dysfunction was 0.9. N-terminal pro-B-type natriuretic peptide levels of patients with sepsis and impaired systolic function were not different from those of patients with sepsis and normal systolic function. The N-terminal pro-B-type natriuretic peptide levels of 20 patients with simple febrile illness were significantly lower.
CONCLUSIONS. N-terminal pro-B-type natriuretic peptide levels are elevated in pediatric patients with sepsis but are higher in some, but not all, patients with acute left ventricular dysfunction. The overlap between N-terminal pro-B-type natriuretic peptide levels in sepsis and acute left ventricular dysfunction precludes the use of the peptide's level as a sole means to differentiate between these conditions. Excessive elevation in N-terminal pro-B-type natriuretic peptide levels, however, suggests cardiac etiology for acute hemodynamic deterioration in infants and children.
Key Words: B-type natriuretic peptide left ventricular dysfunction sepsis infants children
Abbreviations: BNPB-type natriuretic peptide NT-proBNPN-terminal pro-B-type natriuretic peptide LVDleft ventricular dysfunction SIRSsystemic inflammatory-response syndrome
B-type natriuretic peptide (BNP), a member of the natriuretic peptide family, is secreted from cardiac myocytes in response to muscle stretch.1 In recent years, BNP and the N-terminal segment of its prohormone, NT-proBNP, were shown to be very sensitive biochemical markers for cardiac dysfunction both in adults and in children.2 We have reported excessive elevation of NT-proBNP levels in pediatric patients with acute left ventricular dysfunction (LVD).3 Studies in the adult population have found elevated BNP levels in patients with sepsis.4,5 The purpose of this study was to (1) compare NT-proBNP levels in pediatric patients with acute LVD to levels in patients with similar hemodynamic status resulting from sepsis and (2) assess whether NT-proBNP levels can differentiate these 2 disease states.
| PATIENTS AND METHODS |
|---|
|
|
|---|
Patients admitted to 3 PICUs were included. Some of the patients were included in previous publications of the group. Patients with chronic cardiac or renal diseases were excluded. Patients were evaluated clinically and graded by the systemic inflammatory-response syndrome (SIRS) scale.6 SIRS 1 is defined as 2 of the following: fever, tachypnea, tachycardia, and leukocytosis or leukopenia. SIRS 2 is a state with impaired perfusion as manifested by 1 of the following: impaired conscious state, oliguria, hypoxemia, or lactic acidosis. SIRS 3 is an inflammatory state accompanied by shock. Sepsis is defined as SIRS with clear evidence of infection. NT-proBNP levels and echocardiography were performed within 24 hours of the diagnosis of sepsis or acute LVD. Patients were treated as indicated according to their clinical status.
Echocardiography was performed by pediatric cardiologists unaware of the NT-proBNP levels. Systolic left ventricular function was assessed by using M-mode and expressed as shortening fraction. Patients with LVD had a follow-up echocardiogram. Some patients with a definite diagnosis of sepsis had impaired cardiac function; however, the predominant clinical presentation was that of sepsis.
A third group consisted of hemodynamically stable pediatric patients with no history or signs of heart disease who presented with a simple febrile illness. In this group, NT-proBNP levels were measured in plasma that remained after a routine blood count was performed.
For measurement of the NT-proBNP level, blood was collected in tubes containing EDTA. Plasma was separated and stored at 20°C. An electrochemiluminescence immunoassay was performed with the Elecsys system 1010/2010 using the proBNP kit (Roche, Mannheim, Germany). Elecsys proBNP contains polyclonal antibodies that recognize epitopes located in the N-terminal part (176) of proBNP (1108). The assay range is 5 to 35000 pg/mL; higher values were obtained by dilution. The proBNP kit is unaffected by icterus (bilirubin < 35 mg/dL). No cross reactivity was reported with BNP.
Statistical analysis was performed by using the SPSS (SPSS Inc, Chicago, IL). When data were not normally distributed, differences between groups were calculated by using the Mann-Whitney rank-sum test. Correlations were calculated with Pearson's correlation test.
| RESULTS |
|---|
|
|
|---|
|
|
The impact of renal failure on NT-proBNP levels was addressed: in both groups 50% of the patients had acute renal failure, as reflected by plasma creatinine elevation. When patients with renal failure were excluded, NT-proBNP levels were still higher in the children with acute LVD (median: 47120 pg/mL) than in the children with sepsis (median: 2527 pg/mL; P = .03). Among all patients, there was no correlation between creatinine and NT-proBNP levels (P = .7; r = 0.08). Of the 5 patients with sepsis and normal renal function, 4 had normal systolic left ventricular function. Their NT-proBNP levels were elevated (60417, 7558, 1952, and 1115 pg/mL). The 2 patients who died (1 in every group) had NT-proBNP levels below the median of their respective groups (sepsis: 2527 pg/mL; acute LVD: 63260 pg/mL).
| DISCUSSION |
|---|
|
|
|---|
The finding of high levels of NT-proBNP in patients with sepsis needs to be addressed. In adult patients with septic shock, 44% were found to have cardiac dysfunction.10 In our study, 50% of the patients with sepsis were found to have impaired left ventricular function, consistent with the reports in adults. It is interesting to note that NT-proBNP levels of patients with sepsis and impaired systolic function were not different from those of patients with sepsis and normal systolic function.
In this group of patients there were 4 with sepsis and normal cardiac and renal functions. This subgroup of patients had high NT-proBNP levels ranging between 1115 and 60417 pg/mL, much higher than the 95th percentile NT-proBNP level in reference children (350 pg/mL).3 The high NT-proBNP levels in this small group of patients suggest that factors other than cardiac dysfunction may cause elevation of the peptide levels in patients with sepsis.
What is the origin of NT-proBNP in patients with shock? The elevated peptide levels may be a result of increased production, decreased clearance, or both. The peptide may be of cardiac origin or may be secreted by other tissues. One possibility is that the cardiac compromise was not apparent by echocardiography, because diastolic function was not assessed in this study. Sepsis and septic shock are states associated with high cardiac output, and therapy includes administration of fluids. It is possible that cardiac distension occurred, with preserved systolic function causing elevation of BNP secretion. Another possible cause for cardiac secretion of BNP is stress hormones, known to be elevated in a state of shock and to induce BNP synthesis and secretion. Proinflammatory cytokines have been reported to induce BNP synthesis11,12 and probably stimulate the peptide release in a state of sepsis. Other factors or tissues may be responsible for the elevated NT-proBNP levels. One of the suggested candidates is the kidney. High levels of BNP and NT-proBNP were reported in adults with renal failure.13,14 The reason for this phenomenon is not completely understood. It is possible that in this condition there is slower elimination of the peptide. Others have suggested subtle cardiac impairments in patients with renal disease. Patients with chronic renal failure were excluded from this study. However, we have found excessive elevation of NT-proBNP levels in acutely ill children with chronic renal failure. The finding of high NT-proBNP levels in patients with sepsis and normal left ventricular and renal function suggests that a factor or factors other than the heart and kidney are responsible for the elevated peptide levels in patients with sepsis. A significant limitation of this study was the small number of patients. Larger studies are needed to confirm our findings.
| CONCLUSIONS |
|---|
|
|
|---|
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
Address correspondence to Amiram Nir, MD, Shaare Zedek Medical Center, Pediatric Cardiology Unit, PO Box 3235, Jerusalem 91031, Israel. E-mail: amiramn{at}md.huji.ac.il
The authors have indicated they have no financial relationships relevant to this article to disclose.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
I Farombi-Oghuvbu, T Matthews, P D Mayne, H Guerin, and J D Corcoran N-terminal pro-B-type natriuretic peptide: a measure of significant patent ductus arteriosus Arch. Dis. Child. Fetal Neonatal Ed., July 1, 2008; 93(4): F257 - F260. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. El-Khuffash and E. J Molloy Are B-type natriuretic peptide (BNP) and N-terminal-pro-BNP useful in neonates? Arch. Dis. Child. Fetal Neonatal Ed., July 1, 2007; 92(4): F320 - F324. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||